Wan Bangde: The first subject enrolled in the Phase II/III clinical trial of Chishan Jianjia controlled release tablets.

Wanbangde announced that its wholly-owned subsidiary, Wanbangde Pharmaceutical Group Co., Ltd., has completed the inclusion of the first subject in the Phase II/III pivotal registration clinical trial of the novel drug Shishanjianme Controlled-Release Tablets for the treatment of mild to moderate Alzheimer's disease dementia. Shishanjianme Controlled-Release Tablets utilize biphasic controlled-release technology to deliver medication in a smooth peak-valley curve and prolong the release time in the body, achieving fast onset, reducing adverse reactions, and increasing the dosage with good safety. At the same time, controlled-release technology supports once-daily dosing, improving patient convenience and long-term compliance. This clinical trial will comprehensively validate the comprehensive clinical value and benefits of Shishanjianme Controlled-Release Tablets, providing a new choice for Alzheimer's disease treatment.